Published in Contemp Top Immunobiol on January 01, 1984
Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 3.88
Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J Exp Med (2009) 1.14
Aberrant phagocyte function in Shwachman syndrome. Clin Exp Immunol (1987) 0.85
Phagocyte function in juvenile periodontitis. Infect Immun (1990) 0.80
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol (1975) 1.92
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Mechanisms of platelet aggregation by viridans group streptococci. Infect Immun (1987) 1.77
Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun (1980) 1.50
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev (1994) 1.48
Binding of viridans group streptococci to human platelets: a quantitative analysis. Infect Immun (1990) 1.41
Anaphylactoid reactions to vascular graft material presenting with vasodilation and subsequent disseminated intravascular coagulation. Anesthesiology (1989) 1.39
Specific binding of phospholipid platelet-activating factor by human platelets. J Immunol (1982) 1.33
Specific inhibition of the polymorphonuclear leukocyte chemotactic response to hydroxy-fatty acid metabolites of arachidonic acid by methyl ester derivatives. J Clin Invest (1979) 1.32
Alveolar macrophage lipoxygenase products of arachidonic acid: isolation and recognition as the predominant constituents of the neutrophil chemotactic activity elaborated by alveolar macrophages. Cell Immunol (1980) 1.28
Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology (1983) 1.24
The immunological generation of a platelet-activating factor and a platet-lytic factor in the rat. Immunology (1979) 1.07
Alterations in human leukocyte function induced by ingestion of eicosapentaenoic acid. J Clin Immunol (1986) 1.05
Modulation of the random migration of human platelets. J Clin Invest (1974) 1.05
Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. J Infect Dis (1984) 0.98
Immunologic release in the rat peritoneal cavity lipid chemotactic and chemokinetic factors for polymorphonuclear leukocytes. J Immunol (1978) 0.97
Structural requirements for the activity of an immunologically generated lipid chemotactic factor. Immunology (1980) 0.93
Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol (1987) 0.92
Synthesis of platelet activating factor by ocular tissue from inflamed eyes. Arch Ophthalmol (1991) 0.91
Role of immunoglobulin G in platelet aggregation by viridans group streptococci. Infect Immun (1988) 0.91
Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). Am J Pathol (1983) 0.87
Identification of the platelet activating activity in rheumatoid synovial fluid as an intermediate molecular weight complex of IgG. J Immunol (1979) 0.86
Late appearance of phospholipid platelet-activating factor and leukotriene B4 in human skin after repeated antigen challenge. J Allergy Clin Immunol (1989) 0.86
Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. Thromb Res (1987) 0.85
Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Lipids (1991) 0.84
Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. Immunology (1984) 0.84
Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine. J Immunol (1985) 0.83
Synergistic platelet activation by aggregates of IgG and the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine. J Clin Immunol (1986) 0.82
The extracellular and intracellular roles of hydroxy-eicosatetraenoic acids in the modulation of polymorphonuclear leukocyte and macrophage function. J Reticuloendothel Soc (1980) 0.82
Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). Biochem Biophys Res Commun (1985) 0.81
Modulation of human neutrophil and eosinophil polymorphonuclear leukocyte chemotaxis: an analytical review. Clin Immunol Immunopathol (1980) 0.81
Platelet-activating factor stimulates expression of IL-1 beta mRNA in THP-1 cells. Lipids (1991) 0.80
Platelet-activating activity in synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and noninflammatory arthropathies. Arthritis Rheum (1980) 0.79
Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. Thromb Res (1985) 0.78
Potentiation of mitogen-induced human T-lymphocyte activation by retinoic acid. Cancer Res (1985) 0.78
Synergistic increases in IL-1 synthesis by the human monocytic cell line THP-1 treated with PAF and endotoxin. Cell Immunol (1990) 0.78
Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen. J Clin Immunol (1988) 0.77
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer (1996) 0.77
Platelet-activating factor binding to human platelet membranes. Biotechnol Appl Biochem (1986) 0.76
Allergy and immunology: platelet-activating factor. West J Med (1989) 0.75
Indomethacin enhances the proliferation of mitogen-stimulated T lymphocytes of homosexual males with persistent generalized lymphadenopathy. J Clin Immunol (1984) 0.75
Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys (1991) 0.75
Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (1983) 0.75
Lipid mediators of leukocyte function in immediate-type hypersensitivity reactions. Kroc Found Ser (1981) 0.75
Quantitation of arachidonic acid lipoxygenase products in malignant and nonmalignant effusions. Cancer Res (1983) 0.75
Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer. Methods Mol Med (2001) 0.75
Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-SN-glycero-3-phosphorylcholine (ET-18-O-OCH3). Int J Immunopharmacol (1994) 0.75
Selective immobilization of human mononuclear phagocytes by benoxaprofen. Arthritis Rheum (1982) 0.75
Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Cytotherapy (2000) 0.75
Selective activation of human monocytes by the platelet-activating factor analog 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine. J Immunol (1990) 0.75